In this context, ATV can be considered a dual immunotherapeutic agent via a direct immune stimulation by tumor infiltration with CD8+ T cells and depletion of the immune-suppressive Treg cells as well as an antiangiogenic action. The gene discussed is CD8A; the disease is neoplasm.